BioSpace News Archive

NewAmsterdam Pharma Company N.V. today announced the closing of its business combination with Frazier Lifesciences Acquisition Corporation (Nasdaq:FLAC), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners.

Seelos Therapeutics, Inc. today announced that it will hold a research and development update conference call and webcast on Thursday, December 15th from 1pm to 3pm ET.

Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will host a fireside chat and one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 4:20 p.m. Eastern Time.

Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022.

Odyssey Health, Inc., f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, presents a Company update and recap of its concussion drug development program.

Natera, Inc. today announced that Steve Chapman , chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located at the Lotte New York Palace on Wednesday, November 30 at 12:0o p.m. PT.

Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, November 30, 2022, at 10:15am Eastern standard time.

GNS today announced two abstracts and two oral poster presentations highlighting insight from the Gemini Digital Twin models in Alzheimer’s Disease and Multiple Myeloma will be included at the Clinical Trials on Alzheimer’s Disease conference (CTAD) in San Francisco and the American Society of Hematology (ASH) in New Orleans.

The global viscosupplementation market was valued at US$ 3.21 billion in 2021 and it is expected to hit around US$ 5.89 billion by 2030, at a CAGR of 7% over forecast period 2022 to 2030.

The Global Artificial Red Blood Cells market is forecasted to grow at a rate of 21.1% from USD 4.12 billion in 2019 to USD 19.11 billion in 2030.